18
Participants
Start Date
September 2, 2020
Primary Completion Date
December 31, 2025
Study Completion Date
July 31, 2026
Venetoclax
"Dose Level -1: Venetoclax 200 mg/day days 4-8 cycle 1, days 1-5 cycle 2 and 3, + R-GDP~Dose Level 1: Venetoclax 200 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP~Dose Level 2: Venetoclax 400 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP~Dose Level 3: Venetoclax 800 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP"
Rituximab Injection
375 mg/m2 - Day 1, cycle 1.
Rituximab SC
1400 mg fixed dose - Day 1, cycle 2 and 3
Gemcitabine
1000 mg/m2 - Day 1 to day 8
Dexamethasone
40 mg daily - Day 1 to day 4
Cisplatin
75mg/m2 - Day 1
Glofitamab
Cycle 1: Glofitamab 2.5 mg (day 8) and 10 mg (day 15) + R-GDP Cycle 2: Glofitamab 30 mg (day 8) + R-GDP Cycle 3: Glofitamab 30 mg (day 8) + R-GDP
Tafasitamab
Cycle 1: Tafasitamab (12 mg/kg IV day -1, 8, 15) Cycles 2 and 3: Tafasitamab (12 mg/kg IV day 1, 8, 15)
RECRUITING
BCCA - Vancouver, Vancouver
RECRUITING
Kingston Health Sciences Centre, Kingston
RECRUITING
University Health Network, Toronto
RECRUITING
The Jewish General Hospital, Montreal
Collaborators (2)
Roche Pharma AG
INDUSTRY
AbbVie
INDUSTRY
Incyte Corporation
INDUSTRY
Canadian Cancer Trials Group
NETWORK